The US Food and Drug Administration has expanded the indication for a drug to treat previously untreated follicular lymphoma.
Testing for mismatch repair deficiency remains underused among adults with colorectal cancer, despite the existence of well-established guidelines aimed at high-risk populations.
The FDA has granted breakthrough therapy designation to a CAR-T drug for the treatment of patients with relapsed or refractory multiple myeloma.
Laws designed to equalize out-of-pocket costs faced by cancer patients undergoing chemotherapy — whether treated intravenously, with pills or liquid doses — are having mixed results.
Patients with acute myeloid leukemia and good nutritional status have greater 12-month survival rates and shorter hospital stays than patients who are undernourished, according to results of a study.
According to a recent study, symptom burden tends to be high among hospitalized patients with advanced cancer, which leads to increased use of health care resources.
Heart failure patients may be less likely to be hospitalized or die prematurely if they don’t also have diabetes – but even if they do have it, they may still minimize their risk by controlling their blood sugar.
Researchers examined whether low levels of pre-existing cytotoxic tumor-infiltrating lymphocytes can predict the response to antibody- and molecule-based drugs in metastatic HER2-positive breast cancer.
A recent study found that the generic version of capecitabine has yielded less cost savings over a 3-year span than expected, which is likely a reflection of the lack of generic manufacturers entering the market.
A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years.